VistaGen Therapeutics Inc. [NASDAQ: VTGN] closed the trading session at $0.83 on 07/28/20. The day’s price range saw the stock hit a low of $0.75, while the highest price level was $0.86. The company report on July 23, 2020 that VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder.
Company Reaches Consensus with FDA on Key Aspects of Novel Pivotal Phase 3 Study.
Agency Guidance May Provide Significant Time- and Cost-Efficiency for Phase 3 Program.
The stocks have a year to date performance of 20.36 percent and weekly performance of 9.45 percent. The stock has been moved at 11.71 percent over the last six months. The stock has performed 59.91 percent around the most recent 30 days and changed 82.40 percent over the most recent 3-months.
If compared to the average trading volume of 1.57M shares, VTGN reached to a volume of 2365195 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about VistaGen Therapeutics Inc. [VTGN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VTGN shares is $1.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VTGN stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for VistaGen Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 27, 2018. While these analysts kept the previous recommendation, Chardan Capital Markets dropped their target price from $30 to $22. The new note on the price target was released on February 08, 2018, representing the official price target for VistaGen Therapeutics Inc. stock. Previously, the target price had yet another raise to $4, while Maxim Group analysts kept a Buy rating on VTGN stock.
The Average True Range (ATR) for VistaGen Therapeutics Inc. is set at 0.08
VTGN stock trade performance evaluation
VistaGen Therapeutics Inc. [VTGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.45. With this latest performance, VTGN shares gained by 59.91% in over the last four-week period, additionally plugging by 11.71% over the last 6 months – not to mention a rise of 72.94% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VTGN stock in for the last two-week period is set at 74.39, with the RSI for the last a single of trading hit 77.23, and the three-weeks RSI is set at 70.44 for VistaGen Therapeutics Inc. [VTGN]. The present Moving Average for the last 50 days of trading for this stock 0.5457, while it was recorded at 0.7809 for the last single week of trading, and 0.6194 for the last 200 days.
VistaGen Therapeutics Inc. [VTGN]: An insightful look at the core fundamentals
Return on Total Capital for VTGN is now -725.79, given the latest momentum, and Return on Invested Capital for the company is -819.37. Return on Equity for this stock declined to -3,087.23, with Return on Assets sitting at -210.01.
Reflecting on the efficiency of the workforce at the company, VistaGen Therapeutics Inc. [VTGN] managed to generate an average of -$2,308,222 per employee.VistaGen Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.60 and a Current Ratio set at 0.60.
Earnings per share (EPS) analysis for VistaGen Therapeutics Inc. [VTGN] stock
With the latest financial reports released by the company, VistaGen Therapeutics Inc. posted -0.15/share EPS, while the average EPS was predicted by analysts to be reported at -0.11/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -36.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VTGN.
VistaGen Therapeutics Inc. [VTGN]: Insider Ownership positions
There are presently around $2 million, or 11.80% of VTGN stock, in the hands of institutional investors. The top three institutional holders of VTGN stocks are: VANGUARD GROUP INC with ownership of 1,206,983, which is approximately 0.199% of the company’s market cap and around 0.20% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 251,656 shares of the stock with an approximate value of $0.21 million in VTGN stocks shares; and ADVISOR GROUP HOLDINGS, INC., currently with $0.14 million in VTGN stock with ownership of nearly New of the company’s market capitalization.
Positions in VistaGen Therapeutics Inc. stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 8 institutional holders increased their position in VistaGen Therapeutics Inc. [NASDAQ:VTGN] by around 218,417 shares. Additionally, 7 investors decreased positions by around 356,491 shares, while 11 investors held positions by with 1,838,431 shares. The mentioned changes placed institutional holdings at 2,413,339 shares, according to the latest SEC report filing. VTGN stock had 1 new institutional investments in for a total of 171,414 shares, while 3 institutional investors sold positions of 149,398 shares during the same period.